When did BridgeBio Pharma report Q4 2024 earnings?

BridgeBio Pharma (BBIO) reported Q4 2024 earnings on February 20, 2025 before market open.

What were BridgeBio Pharma's Q4 2024 revenue and EPS?

BridgeBio Pharma reported revenue of $5.9M and diluted EPS of $-1.31 for Q4 2024.

Did BridgeBio Pharma beat estimates in Q4 2024?

Revenue beat the consensus estimate of $4.0M by $1.8M. EPS missed the consensus estimate of $-1.09 by $0.22.

Where can I find BridgeBio Pharma's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-024119) directly on SEC EDGAR. The filing index links above go to sec.gov.

BridgeBio Pharma BBIO Q4 2024 Annual earnings

Reported February 20, 2025 · Before market open

Revenue$5.9MBeat by $1.8M Diluted EPS-$1.31Miss by $0.22

Revenue estimate$4.0M

EPS estimate-$1.09

Next report

Aug 4, 2026 (In 3 weeks)

Revenue estimate$220.2M

EPS estimate-$0.64

Financials

Q4 2024

Income statement

See full

Revenue$5.9M+237%

Gross profit$3.8M+231%

Operating income-$226.0M-27.4%

Net income-$267.4M-57.0%

EPS (diluted)-$1.42-47.9%

Balance sheet

See full

Cash & equivalents$683.2M+81.7%

Total debt$446.5M-2.8%

Total equity-$1.5B-8.4%

Total assets$919.3M+68.3%

Cash flow

See full

Operating cash flow-$195.3M-56.5%

CapEx$47.0K-89.2%

Free cash flow-$195.4M-56.0%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$5.19B-26.2%

Enterprise value$4.95B-30.4%

P/S23.4×-732×

Profitability

See full

Gross margin98.3%+24.5pp

Operating margin-267.2%-131pp

Net margin-244.9%-120pp

Returns & leverage

See full

Current ratio4.7×+1.3×

Versus estimates

Revenue

Q1 2026$194.5MBeat by $16.4M Q4 2025$154.2MBeat by $7.3M Q3 2025$120.7MMiss by $27.5M Q2 2025$110.6MBeat by $2.4M Q1 2025$116.6MBeat by $48.2M

Q4 2024$5.9MBeat by $1.8M

Diluted EPS

Q1 2026-$0.84Miss by $0.14 Q4 2025-$1.00Miss by $0.29 Q3 2025-$0.95Miss by $0.07 Q2 2025-$0.95Miss by $0.12 Q1 2025-$0.88Beat by $0.12

Q4 2024-$1.31Miss by $0.22

Ask the moment BridgeBio Pharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did BridgeBio Pharma report Q4 2024 earnings?: BridgeBio Pharma (BBIO) reported Q4 2024 earnings on February 20, 2025 before market open.
What were BridgeBio Pharma's Q4 2024 revenue and EPS?: BridgeBio Pharma reported revenue of $5.9M and diluted EPS of $-1.31 for Q4 2024.
Did BridgeBio Pharma beat estimates in Q4 2024?: Revenue beat the consensus estimate of $4.0M by $1.8M. EPS missed the consensus estimate of $-1.09 by $0.22.
Where can I find BridgeBio Pharma's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-024119) directly on SEC EDGAR. The filing index links above go to sec.gov.